131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.

Conclusions: <br />These findings demonstrate the theranostic potential of [(131)I]SGMIB-2Rs15d. An initial scan using low radioactive [*I]SGMIB-2Rs15d allows patient selection and dosimetry calculations for subsequent therapeutic [(131)I]SGMIB-2Rs15d, and could thereby impact therapy outcome on HER2(+) BC patients.
PMID: 28751451 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 27, 2017 Category: Cancer & Oncology Authors: D'Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, Raes G, Caveliers V, Zalutsky M, Lahoutte T, Devoogdt N Tags: Clin Cancer Res Source Type: research